• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Recilisib Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754383

MBS5754383 is an inhibitor targeting Recilisib. Recilisib is a radioprotectant,can activate AKT, PI3K activities in cells. More details

Please Inquire
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Recilisib, Inhibitor
Full Product Name
Recilisib
Product Synonym Names
Ex-RAD; ON 01210
Form/Format
Powder
Preparation and Storage
Store at -20°C for 2 years powder
Molecular Weight
336.79
Solubility
DMSO: 35.71mg/mL (106.03mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C16H13ClO4S
CAS Number
334969-03-8
Target & IC50
Akt
PI3K
In Vivo
The rate of recovery and differentiation of primitive bone marrow myeloid progenitor cells in mice significantly increased by Recilisib Sodium. Recilisib Sodium in combination with radiation reduces CFU numbers in mice, but the Recilisib Sodium-treated mice consistently retain a capability to form differentiated colonies. Recilisib Sodium treated mice have a progenitor cell population that is never completely depleted by radiation exposure.
In Vitro
Recilisib Sodium increases PI3K activity in HFL-1 cells and murine bone marrow cells in response to radiation exposure. Recilisib Sodium treatment in combination with radiation alters the MAPK signaling pathway.

Product Categories/Family for Recilisib, inhibitor

Cytoskeletal Signaling; PI3K/Akt/mTOR signaling

Structure of Recilisib, inhibitor

Recilisib, CAS 334969-03-8
Recilisib Inhibitor – Cat# MBS5754383

Testing Data of Recilisib, inhibitor

Recilisib Inhibitor, Testing Data – Cat# MBS5754383

Product References and Citations for Recilisib, inhibitor

Kang AD, et al. ON01210.Na (Ex-RAD) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013;8(3):e58355.
Kang AD, et al. ON01210.Na (Ex-RAD) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013;8(3):e58355.

Other Notes

Small volumes of Recilisib, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000